Catterton Partners acquires StriVectin skin care brand, related assets

GREENWICH, Conn. Private equity firm Catterton Partners has acquired the StriVectin skin care brand and related assets from affiliates of Klein-Becker through a holding company. Terms of the deal were not disclosed.

Chrysallis, a management team in the beauty and personal care industry, led by CEO Melisse Shaban and CMO Jill Scalamandre, will lead the new company.

The partnership between Catterton and the Chrysallis management team marks another in a number of endeavors between the two groups, the most notable of which was Frederic Fekkai & Co., which was sold in 2008.

"StriVectin's record of profitable growth is a tribute to its customer centric marketing and targeted formulations, which helped create the cosmeceutical skin care category. With this transaction, we intend to build on these strengths and our own expertise to further enhance StriVectin's product portfolio and extend its global reach. We will be looking at new technologies to strengthen StriVectin's strong clinical positioning, thereby increasing value to the end consumer," stated Shaban.

StriVectin is expected to reach $58.2 billion by 2012, an increase of 17.6% since 2007, according to Datamonitor data. Lauded as the "stretch-mark cream turned anti-wrinkle phenomenon" since being introduced in 2003, StriVectin is the fastest growing anti-aging brand and one of the top 20 prestige skincare brands in the United States, stated Catterton, citing data from NPD Group.

Today, the StriVectin line encompasses a range of anti-aging products with a targeted, problem-solution positioning, including StriVectin Instant Facial Sculpting Cream, StriVectin-SD Eye Cream, StriVectin Neck Cream, and StriVectin-WF Instant Deep Wrinkle Filler.

StriVectin products are sold through retailers as well as direct marketing channels around the world, with the largest presence in the United States, France and the United Kingdom.